Aim: To establish clinical practice for the treatment of patients with atopic dermatitis (eczema) patients attending dermatology outpatient department. Material and methods: A proper informed consent was taken after explaining the study to the patients in a language they could understand. A total of 50 prescriptions issued to patients attending the OPD dermatology were entered in the case record forms following counsultation. The prescriptions were collected for a period of 3 months. It includes the patients who agree to participate in study by signing informed consent form, both male and female patients of age group 11 to 60 years and patients with confirmatory diagnosis of AD. The patients with comorbidities, patients with incomplete data and inconsistent diagnosis of AD, pregnant women, breast feeding women, neonates, geriatrics (>60 years), and patients using alternative system of medicine (other than allopathy) were excluded from the study. Results: In a total of 50 prescriptions, 100 drugs were prescribed. The average number of drugs per prescription was found to be 2. Of total 100 drugs, 30 medications were oral preparations and 70 medications were topical formulations. The number of prescriptions of antihistamines were 27 constituted percentages of 27%, oral antibiotics were 5 with a percentage of 5%, oral antifungals were 4 with a percentage of 4%, vitamin supplements were 8 constituted a percentage of 8%, topical antibiotics were 3 constituted a percentage of 3%, topical antifungals were 10 constituted a percentage of 10%, topical steroids were 12 with a percentage of 12%, and emollients were 31 with a percentage of 31%. In our study, two classes of drugs largely prescribed by the dermatologists were antihistamines and emollients. In a total of 100 prescribed medications, 27 antihistamines and 31 emollients were given to patients during the study period. Conclusion: AD is a chronic inflammatory dermatological disorder, mainly characterized by itching, pruritis, rashes, redness. In clinical practice guidelines and position statements concerning the management of AD, the use of systemic CS, including prednisone, hydrocortisone and celestone, is generally discouraged, while systemic CS can lead to rapid clearing of AD, their side effect profile and the risk of severe rebound flares after discontinuation limit their use.